JAK2 and tuberculosis: Baricitinib, a selective JAK1 and JAK2 inhibitor, may predispose to tuberculosis by suppressing interferon-gamma (IFN-γ)-mediated signaling, which is essential for macrophage activation and granuloma maintenance [9].